Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


About Us
Corporate Strategy
Contacts

Being private, APR is not under any obligation to disclose its financial results and reports as well as to disclose any material information.
However, APR would be happy to provide under request any additional information.













Please send your request to: Paolo Galfetti, CEO at paolo.galfetti@apr.ch or call +41.91.6957020
In a nutshell APR is debt free, cash positive and profitable.



Search results